{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01416878,0.000688975,0.002517689,0.002578683,0.0004301481,0.004052018,0.001793608,0.002682287,0.006343753],"category_scores_gemma":[0.01234088,0.0003481357,0.00161824,0.003493841,0.001605727,0.008631899,0.001183914,0.002778366,0.001318289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002701708,"about_ca_system_score_gemma":0.00548165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001846644,"about_ca_topic_score_gemma":0.004933643,"domain_scores_codex":[0.9962279,0.001969558,0.0006444554,0.0003384766,0.0006376602,0.0001820164],"domain_scores_gemma":[0.981898,0.01172489,0.002711343,0.0003950382,0.002646659,0.0006240165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001253961,0.0001876102,0.002296852,0.03181102,0.0004077803,0.0002449536,0.0003134115,0.0007006039,0.001774346,0.01060444,0.0264985,0.9239065],"study_design_scores_gemma":[0.0008238081,0.002384123,0.009347972,0.1077037,0.002546017,0.002148172,0.002174199,0.00210026,0.001109591,0.03761673,0.831893,0.0001524185],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001089607,0.9770325,0.0004462257,0.02020938,0.0003576458,0.00001422488,0.00005514418,0.00002195143,0.0007733474],"genre_scores_gemma":[0.01496889,0.9673589,0.001917104,0.01322636,0.001717507,0.00005474023,0.0001279802,0.00002414723,0.0006042157],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01416878,"threshold_uncertainty_score":0.07493252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05377138215085864,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}